Cabaletta Bio

Cabaletta Bio(CABA)

PHILADELPHIA, PA
Biotechnology

Focus: Chimeric Auto Antibody Receptors

Cabaletta Bio is a life sciences company focused on Chimeric Auto Antibody Receptors.

Oncology
Funding Stage
PUBLIC
Open Jobs
13

Pipeline & Clinical Trials

Phase 1
Clinical Trials (1)
NCT05451212Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis
Phase 1
Phase 1/2
Clinical Trials (1)
NCT06328777RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Phase 1/2
Clinical Trials (1)
NCT06121297RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT04422912A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Phase 1/2
Clinical Trials (1)
NCT06359041RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Phase 1/2
Clinical Trials (1)
NCT07006805RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis
Phase 1/2
CABA-201 following preconditioning with fludarabine and cyclophosphamide
Idiopathic Inflammatory Myopathy
Phase 2/3
Clinical Trials (1)
NCT06154252RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Phase 2/3

Open Jobs (13)

Interview Prep Quick Facts
Founded: 2018
Portfolio: 7 clinical trials
Top TAs: Neurology, Immunology
SEC Filings: 2 available
Open Roles: 13 active jobs
Therapeutic Area Focus
Neurology
3 pipeline
Immunology
1 pipeline
Marketed
Pipeline

Financials (FY2024)

R&D Spend
$55M41%
Net Income
-$68M
Cash
$193M